Evidence map›Paper›PMID 34543293›Full record

ArticlePLoS neglected tropical diseases2021

Surveillance for peri-elimination trachoma recrudescence: Exploratory studies in Ghana.

Laura Senyonjo, James Addy, Diana L Martin, David Agyemang, Dorothy Yeboah-Manu, Sarah Gwyn, Benjamin Marfo, Adwoa Asante-Poku, Agatha Aboe, Ernest Mensah and 2 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Trachoma.Lancet (London, England) · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Laura SenyonjoResearch Team, Sightsavers, Haywards Heath, United Kingdom.ORCID 0000-0002-4533-3162
James AddyEye Health Department, Ghana Health Service, Accra, Ghana.ORCID 0000-0001-5542-3770
Diana L MartinDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, United States of America.
David AgyemangSightsavers Ghana, Accra, Ghana.ORCID 0000-0002-7571-4695
Dorothy Yeboah-ManuBacteriology Department, Noguchi Memorial Institute for Medical Research, Accra, Ghana.
Sarah GwynDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, United States of America.
Benjamin MarfoNeglected Tropical Diseases Division, Ghana Health Service, Accra, Ghana.
Adwoa Asante-PokuBacteriology Department, Noguchi Memorial Institute for Medical Research, Accra, Ghana.ORCID 0000-0001-8929-193X
Agatha AboeSightsavers Ghana, Accra, Ghana.
Ernest MensahNTD team, FHI360, Accra, Ghana.
Anthony W SolomonClinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0001-7101-6649
Robin L BaileyClinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0002-8770-1680

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo date, eleven countries have been validated as having eliminated trachoma as a public health problem, including Ghana in 2018. Surveillance for recrudescence is needed both pre- and post-validation but evidence-based guidance on appropriate strategies is lacking. We explored two potential surveillance strategies in Ghana. METHODOLOGY/PRINCIPAL

findingsAmongst randomly-selected communities enrolled in pre-validation on-going surveillance between 2011 and 2015, eight were identified as having had trachomatous-inflammation follicular (TF) prevalence ≥5% in children aged 1-9 years between 2012 and 2014. These eight were re-visited in 2015 and 2016 and neighbouring communities were also added ("TF trigger" investigations). Resident children aged 1-9 years were then examined for trachoma and had a conjunctival swab to test for Chlamydia trachomatis (Ct) and a dried blood spot (DBS) taken to test for anti-Pgp3 antibodies. These investigations identified at least one community with evidence of probable recent Ct ocular transmission. However, the approach likely lacks sufficient spatio-temporal power to be reliable. A post-validation surveillance strategy was also evaluated, this reviewed the ocular Ct infection and anti-Pgp3 seroprevalence data from the TF trigger investigations and from the pre-validation surveillance surveys in 2015 and 2016. Three communities identified as having ocular Ct infection >0% and anti-Pgp3 seroprevalence ≥15.0% were identified, and along with three linked communities, were followed-up as part of the surveillance strategy. An additional three communities with a seroprevalence ≥25.0% but no Ct infection were also followed up ("antibody and infection trigger" investigations). DBS were taken from all residents aged ≥1 year and ocular swabs from all children aged 1-9 years. There was evidence of transmission in the group of communities visited in one district (Zabzugu-Tatale). There was no or little evidence of continued transmission in other districts, suggesting previous infection identified was transient or potentially not true ocular Ct infection. CONCLUSIONS/SIGNIFICANCE: There is evidence of heterogeneity in Ct transmission dynamics in northern Ghana, even 10 years after wide-scale MDA has stopped. There is added value in monitoring Ct infection and anti-Ct antibodies, using these indicators to interrogate past or present surveillance strategies. This can result in a deeper understanding of transmission dynamics and inform new post-validation surveillance strategies. Opportunities should be explored for integrating PCR and serological-based markers into surveys conducted in trachoma elimination settings.

Indexed as

Epidemiological MonitoringPopulation SurveillanceAntibodies, BacterialChildChild, PreschoolChlamydia trachomatisDried Blood Spot TestingFemaleGhanaHumansInfantMaleReproducibility of ResultsTrachomaAntibodies, Bacterial

Identifiers

PMID34543293
PMCPMC8519445

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.